Under one in 10 patients who could benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it publishes its initial advice on the therapies.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is calling for broader and more equitable availability to this class of drugs.
According to forecasts, more than two billion will be obese by 2030 unless action is taken.
"Our new guidelines recognises that obesity is a long-term condition that can be managed with comprehensive and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are significant barriers to universal availability to the treatments that can help people shift considerable weight, explains the organization.
GLP-1 Therapy Scarcity
Even in the present best projected outlook, the production of these medications might only reach around 100 million people – under 10% of eligible patients, as stated by the WHO.
The recommendation encourages governments and firms to expand availability, by approaches like patent sharing.
The intellectual property rights on semaglutide – the core ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Obesity Injections Operate
These medications replicate a biological compound to slow digestion, reduce hunger and enhance satiety so users reduce food intake.
People typically start to lose weight within a few weeks of beginning the weekly injections.
Evidence points to people may regain a significant portion after a year of discontinuing the drug, when their usual hunger return.
Being overweight or obese increases your chance for contracting health problems, like diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns individuals in every country and was associated with over three and a half million fatalities worldwide in 2024, per the health agency.
